Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Zai Lab Limited - American Depositary Shares (NQ:ZLAB)

17.04 -0.60 (-3.40%)
Streaming Delayed Price Updated: 2:40 PM EST, Jan 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 601,011
Open 17.60
Bid (Size) 17.04 (300)
Ask (Size) 17.05 (300)
Prev. Close 17.64
Today's Range 17.01 - 17.88
52wk Range 16.82 - 44.34
Shares Outstanding 956,637,360
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO™ (repotrectinib) for Patients with NTRK-Positive Solid Tumors
From Zai Lab Limited
Via Business Wire

Performance

YTD
-1.7%
-1.7%
1 Month
-4.4%
-4.4%
3 Month
-35.3%
-35.3%
6 Month
-56.0%
-56.0%
1 Year
-36.5%
-36.5%

More News

Read More
News headline image
Zai Lab to Present at 44th Annual J.P. Morgan Healthcare Conference
From Zai Lab Limited
Via Business Wire
News headline image
Earnings Scheduled For November 6, 2025 ↗
Via Benzinga
Zai Lab To Await More Trial Data Before Filing For Regulatory Approval For Experimental Cancer Drug ↗
Via Stocktwits
News headline image
Earnings Scheduled For August 7, 2025 ↗
Via Benzinga
News headline image
Zai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces Updates to China’s National Reimbursement Drug List
From Zai Lab Limited
Via Business Wire
News headline image
Nuvation Bio (NUVB) Soars on IBTROZI's Blockbuster Launch and Stellar Q3 2025 Performance
Via MarketMinute
News headline image
Zai Lab Announces Third Quarter 2025 Financial Results and Recent Corporate Updates
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces Participation in Investor Conferences in November and December 2025
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational Study
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab to Announce Third Quarter 2025 Financial Results and Recent Corporate Updates on November 6, 2025
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab's Double Whammy: Earnings Miss, Phase 3 Setback ↗
Via Benzinga
Topics Earnings
News headline image
China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order ↗
Via Investor's Business Daily
Topics Government
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zai Lab Limited - ZLAB
From Pomerantz LLP
Via GlobeNewswire
News headline image
Amgen Faces Setback As Final Data Weakens Case For Gastric Cancer Drug ↗
Via Benzinga
News headline image
C3.ai Posts Downbeat Results, Joins GitLab, Salesforce And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
Via Benzinga
News headline image
Zai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces Participation in Investor Conferences in September 2025
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces China National Medical Products Administration Grants Innovative Medical Device Designation for Tumor Treating Fields for Patients with Pancreatic Cancer
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Establishes Oncology Scientific Advisory Board
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces Second Quarter 2025 Financial Results and Recent Corporate Updates
From Zai Lab Limited
Via Business Wire

Frequently Asked Questions

Is Zai Lab Limited - American Depositary Shares publicly traded?
Yes, Zai Lab Limited - American Depositary Shares is publicly traded.
What exchange does Zai Lab Limited - American Depositary Shares trade on?
Zai Lab Limited - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Zai Lab Limited - American Depositary Shares?
The ticker symbol for Zai Lab Limited - American Depositary Shares is ZLAB on the Nasdaq Stock Market
What is the current price of Zai Lab Limited - American Depositary Shares?
The current price of Zai Lab Limited - American Depositary Shares is 17.04
When was Zai Lab Limited - American Depositary Shares last traded?
The last trade of Zai Lab Limited - American Depositary Shares was at 01/27/26 02:40 PM ET
What is the market capitalization of Zai Lab Limited - American Depositary Shares?
The market capitalization of Zai Lab Limited - American Depositary Shares is 16.30B
How many shares of Zai Lab Limited - American Depositary Shares are outstanding?
Zai Lab Limited - American Depositary Shares has 16B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.